The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
about
My treatment approach to rheumatoid arthritisInterleukin 15 levels in serum may predict a severe disease course in patients with early arthritisDecreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohortAnalysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells.A non-parametric method for building predictive genetic tests on high-dimensional data.Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB studyValidity of clinical associations of biomarkers in translational research studies: the case of systemic autoimmune diseasesEffects of laser treatment on the expression of cytosolic proteins in the synovium of patients with osteoarthritis.Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.Association between arthritis score at the onset of the disease and long-term locomotor outcome in adjuvant-induced arthritis in ratsLong-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis.Rheumatoid arthritis. Evidence for a genetic component to disease severity in RAA multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt studyAssociation of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexateReview of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?Developments in the clinical understanding of rheumatoid arthritis.Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis.Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: A case report.Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA.Genomics and proteomics: Applications in autoimmune diseases.Anti-Cyclic Citrullinated Peptide Antibody-Positive Meningoencephalitis in the Preclinical Period of Rheumatoid Arthritis.Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point.Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis.Autoantibodies, C-reactive protein, erythrocyte sedimentation rate and serum cytokine profiling in monitoring of early treatment.The pathogenesis of rheumatoid arthritis: new insights from old clinical data?Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.A case of rheumatoid meningitis: pathologic and magnetic resonance imaging findings.Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
P2860
Q26829955-A4C0E1FF-0111-4134-B596-7058586FC00AQ28740658-3B9DD9AF-EB6B-4537-8159-7A5F94E0D2DEQ30839061-1863FAE3-B79D-4269-BC33-6B1CA080D7A4Q33901019-35111677-93A8-4ADD-8EC2-AD5289ADE729Q33967840-A9A60F98-4874-48C1-8B7D-8324843C0845Q33968506-C2D2EAAA-F6F8-4FBE-BE17-099A0EA5E4BEQ34346280-87E59EB8-5DE5-430A-B306-5297784C0F39Q35183633-C0BDE366-7EFF-495B-9C7A-76D7AAB8B02FQ35617658-CB094678-A805-4174-9AC3-06806EFEBD0DQ35632933-20E5A3EB-1BBC-487C-B28A-8C9C2619CCBFQ35863335-8BA92FB5-F210-42F0-9454-318C5A87217AQ36245951-F2D7C565-7F9B-40FA-AECD-7275BDDD120CQ36890843-C8B4C3B0-8A26-4DAC-8950-DC7245980C49Q36936691-62B42DBC-0023-429D-A07C-7597223185C4Q36939442-F3168E12-74C5-4EB5-87FE-4AA47CFE0942Q37093920-114590AA-8876-49A7-BE62-1F74327ADB89Q37207010-725A9350-B04B-4738-8DAC-CDAF571D514AQ37270792-BE35F6AB-4D3A-47E0-B37A-651EBDAC55D8Q37445090-9B9A9C90-F26C-40CE-9A30-7DEC532567D5Q37646610-A361A87F-6B3C-4947-AE34-6E885821CED6Q37976262-E4B0FC10-6115-40EB-BF09-CCD61A3EF5B2Q38066181-A428476A-8322-42E5-8B07-C7FFE063311CQ40085886-E04BF6EB-5DE0-4EEE-8197-27F8EBE42304Q40484774-E9D3E3ED-61E8-413F-886C-EED023C3BE1DQ42540679-19FF67A6-5FE2-4B0C-BEBE-66CC13996929Q43538492-1B4B43C3-849A-433A-9DB1-E9D6F2DFD394Q47331625-EC39E58E-98F0-4DA2-B176-1C528B1B05DFQ48029200-82729FF1-1F7B-49C8-80BC-1DE6696C3499Q48030951-09F737E7-98A1-4F47-AD55-FD3E6A4370D3Q48935869-659DFD58-369C-4AA5-B08C-89DDDFD5AE68Q54460498-548288E1-C0DD-4C7E-9033-9292CE675835
P2860
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The need for prognosticators i ...... cal markers: where are we now?
@ast
The need for prognosticators i ...... cal markers: where are we now?
@en
type
label
The need for prognosticators i ...... cal markers: where are we now?
@ast
The need for prognosticators i ...... cal markers: where are we now?
@en
prefLabel
The need for prognosticators i ...... cal markers: where are we now?
@ast
The need for prognosticators i ...... cal markers: where are we now?
@en
P2093
P2860
P356
P1476
The need for prognosticators i ...... cal markers: where are we now?
@en
P2093
Daniel Aletaha
Günter Steiner
Johannes Grisar
Kurt Redlich
Oswald Wagner
P2860
P2888
P356
10.1186/AR2418
P577
2008-05-29T00:00:00Z
P5875
P6179
1024910315